HomeCompareSPIN vs MRK

SPIN vs MRK: Dividend Comparison 2026

SPIN yields 8.50% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPIN wins by $4.4K in total portfolio value
10 years
SPIN
SPIN
● Live price
8.50%
Share price
$30.26
Annual div
$2.57
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.1K
Annual income
$1,453.61
Full SPIN calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — SPIN vs MRK

📍 SPIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPINMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPIN + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPIN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPIN
Annual income on $10K today (after 15% tax)
$722.31/yr
After 10yr DRIP, annual income (after tax)
$1,235.57/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, SPIN beats the other by $427.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPIN + MRK for your $10,000?

SPIN: 50%MRK: 50%
100% MRK50/50100% SPIN
Portfolio after 10yr
$32.9K
Annual income
$1,201.95/yr
Blended yield
3.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SPIN
No analyst data
Altman Z
-0.9
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPIN buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPINMRK
Forward yield8.50%3.25%
Annual dividend / share$2.57$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$35.1K$30.7K
Annual income after 10y$1,453.61$950.29
Total dividends collected$11.5K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPIN vs MRK ($10,000, DRIP)

YearSPIN PortfolioSPIN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,550$849.78$11,192$351.54+$358.00SPIN
2$13,276$917.26$12,524$392.70+$752.00SPIN
3$15,190$985.35$14,015$438.65+$1.2KSPIN
4$17,307$1,053.70$15,682$489.96+$1.6KSPIN
5$19,641$1,122.01$17,547$547.23+$2.1KSPIN
6$22,206$1,189.99$19,632$611.16+$2.6KSPIN
7$25,017$1,257.37$21,963$682.53+$3.1KSPIN
8$28,092$1,323.91$24,571$762.18+$3.5KSPIN
9$31,448$1,389.39$27,486$851.08+$4.0KSPIN
10$35,103$1,453.61$30,745$950.29+$4.4KSPIN

SPIN vs MRK: Complete Analysis 2026

SPINStock

The State Street US Equity Premium Income ETF employs an actively managed strategy that is designed to provide current income while maintaining the potential for long-term growthThe fund invests in a portfolio of large- and mid-cap US stocks that the investment advisor believes exhibit desirable characteristics such as strong fundamentals, attractive valuations, and long-term growth prospects, while dynamically selling call options on a US large-cap exposure, such as the S&P 500 Index, to generate additional monthly incomeThe strategy utilizes a proprietary macroeconomic signal to determine the option strikes (moneyness) of the calls written, seeking to harvest higher option premiums during volatile market conditions to help provide more of a cushion against possible losses in the underlying portfolio, while harvesting lower option premiums during low-risk market conditions which may allow the fund to participate in greater potential market upside

Full SPIN Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this SPIN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPIN vs SCHDSPIN vs JEPISPIN vs OSPIN vs KOSPIN vs MAINSPIN vs JNJSPIN vs ABBVSPIN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.